Jivi (Damoctocog Alfa Pegol)

• Jivi is used to manage hemophilia A, a congenital factor VIII deficiency, by providing replacement therapy.
• Hemophilia A (prophylaxis): maintains clotting factor levels to prevent spontaneous bleeding episodes.
• Hemophilia A (on‑demand treatment): controls acute bleeding episodes when they occur.
• Surgical procedures in hemophilia A patients: provides hemostasis to reduce peri‑operative bleeding.

• Damoctocog Alfa Pegol is a recombinant, pegylated factor VIII protein that binds to activated factor IXa on phospholipid surfaces, forming the intrinsic tenase complex. This restores the conversion of factor X to Xa, re‑establishing the intrinsic pathway of the coagulation cascade and generating thrombin to form a stable fibrin clot. The pegylation prolongs plasma half‑life, allowing sustained activity after a single infusion.

The safety profile of Jivi includes both common and rare adverse reactions observed in clinical use.

Common Side Effects

• Injection site pain: mild discomfort at the infusion site.
• Headache: transient headache during or after infusion.
• Fever: low‑grade temperature elevation.
• Nausea: mild gastrointestinal upset.
• Arthralgia: joint pain.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Development of factor VIII inhibitors: neutralizing antibodies that reduce efficacy.
• Anaphylactic reactions: severe allergic response requiring immediate medical attention.
• Thromboembolic events: clot formation in vessels.
• Hepatic dysfunction: elevated liver enzymes.
• Disseminated intravascular coagulation: widespread clotting and bleeding.
• Severe allergic reactions: including angioedema.

When prescribing Jivi, healthcare professionals should observe several precautionary measures to ensure safe use.

• Inhibitor monitoring: regularly test for anti‑factor VIII antibodies that may diminish treatment effect.
• Bleeding history assessment: evaluate patient’s prior bleeding episodes and current anticoagulant use.
• Liver function evaluation: check hepatic enzymes before initiating therapy.
• Cardiovascular risk: use cautiously in patients with a history of thrombosis.
• Hypersensitivity: avoid in individuals with known allergy to any component of the product.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Jivi may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Concurrent use of other factor VIII concentrates: may increase risk of inhibitor development.
• Therapeutic anticoagulants (e.g., warfarin, heparin): can reduce clotting efficacy of Jivi.
• Immune tolerance induction agents: may interfere with antibody response.

Moderate Interactions (Monitor Closely)

• Antifibrinolytics (e.g., tranexamic acid): may enhance hemostatic effect, requiring monitoring for thrombosis.
• Certain antibiotics (e.g., aminoglycosides): can affect laboratory clotting assays, necessitating dose adjustments.
• Vaccinations: may transiently alter immune response, monitor for inhibitor formation.